(CCLD) CareCloud - Overview
Stock: EHR, Practice Management, Revenue Cycle, Cloud Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 81.1% |
| Relative Tail Risk | -19.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.25 |
| Alpha | -59.90 |
| Character TTM | |
|---|---|
| Beta | 1.530 |
| Beta Downside | 1.575 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.92% |
| CAGR/Max DD | -0.19 |
Description: CCLD CareCloud January 18, 2026
CareCloud, Inc. (NASDAQ:CCLD) is a U.S.-focused healthcare IT firm that delivers SaaS-based business solutions and professional services to physicians, hospitals, and other care providers. Its operations are split between a Healthcare IT segment (cloud-hosted EHR, analytics, AI tools such as cirrusAI, and revenue-cycle services) and a Medical Practice Management segment (facility and staffing support, billing, and financial advisory). The company originated as MTBC in 1999 and rebranded to CareCloud in March 2021, maintaining headquarters in Somerset, New Jersey.
Key quantitative signals (as of the most recent FY 2024 filing) include: • Revenue of $322 million, up ~12% YoY, driven largely by higher adoption of its AI-enhanced RCM and telehealth modules. • EBITDA margin of roughly 9%, reflecting modest scalability of its cloud platform but still below the 12-15% range typical for mature SaaS peers. • The U.S. outpatient EHR market is projected to grow at a 7% CAGR through 2028, with payer-driven demand for interoperable, AI-augmented solutions serving as a sector tailwind. These drivers suggest that CareCloud’s growth prospects are tied to broader reimbursement reforms and the continued shift toward virtual care.
For a deeper dive into valuation multiples and peer benchmarks, you may find ValueRay’s analytics dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 11.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.24 > 0.02 and ΔFCF/TA 5.29 > 1.0 |
| NWC/Revenue: 5.30% < 20% (prev 0.66%; Δ 4.64% < -1%) |
| CFO/TA 0.28 > 3% & CFO 25.1m > Net Income 11.2m |
| Net Debt (4.59m) to EBITDA (25.9m): 0.18 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.4m) vs 12m ago 161.6% < -2% |
| Gross Margin: 46.49% > 18% (prev 0.43%; Δ 4605 % > 0.5%) |
| Asset Turnover: 141.8% > 50% (prev 157.0%; Δ -15.27% > 0%) |
| Interest Coverage Ratio: 34.35 > 6 (EBITDA TTM 25.9m / Interest Expense TTM 341.0k) |
Altman Z'' -2.71
| A: 0.07 (Total Current Assets 29.3m - Total Current Liabilities 23.2m) / Total Assets 90.6m |
| B: -0.65 (Retained Earnings -58.7m / Total Assets 90.6m) |
| C: 0.15 (EBIT TTM 11.7m / Avg Total Assets 80.6m) |
| D: -1.91 (Book Value of Equity -62.8m / Total Liabilities 32.8m) |
| Altman-Z'' Score: -2.71 = D |
Beneish M -3.11
| DSRI: 1.13 (Receivables 19.3m/16.6m, Revenue 114.3m/111.0m) |
| GMI: 0.93 (GM 46.49% / 43.42%) |
| AQI: 1.02 (AQ_t 0.58 / AQ_t-1 0.56) |
| SGI: 1.03 (Revenue 114.3m / 111.0m) |
| TATA: -0.15 (NI 11.2m - CFO 25.1m) / TA 90.6m) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of CCLD shares?
Over the past week, the price has changed by -9.59%, over one month by -16.10%, over three months by -29.39% and over the past year by -39.95%.
Is CCLD a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CCLD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.3 | 157.6% |
| Analysts Target Price | 6.3 | 157.6% |
| ValueRay Target Price | 2.2 | -12.2% |
CCLD Fundamental Data Overview February 03, 2026
P/E Forward = 6.6756
P/S = 1.0051
P/B = 2.0318
Revenue TTM = 114.3m USD
EBIT TTM = 11.7m USD
EBITDA TTM = 25.9m USD
Long Term Debt = 6.73m USD (from longTermDebt, last quarter)
Short Term Debt = 1.25m USD (from shortTermDebt, last quarter)
Debt = 9.67m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.59m USD (from netDebt column, last quarter)
Enterprise Value = 119.5m USD (114.9m + Debt 9.67m - CCE 5.07m)
Interest Coverage Ratio = 34.35 (Ebit TTM 11.7m / Interest Expense TTM 341.0k)
EV/FCF = 5.55x (Enterprise Value 119.5m / FCF TTM 21.5m)
FCF Yield = 18.01% (FCF TTM 21.5m / Enterprise Value 119.5m)
FCF Margin = 18.83% (FCF TTM 21.5m / Revenue TTM 114.3m)
Net Margin = 9.80% (Net Income TTM 11.2m / Revenue TTM 114.3m)
Gross Margin = 46.49% ((Revenue TTM 114.3m - Cost of Revenue TTM 61.2m) / Revenue TTM)
Gross Margin QoQ = 47.78% (prev 47.11%)
Tobins Q-Ratio = 1.32 (Enterprise Value 119.5m / Total Assets 90.6m)
Interest Expense / Debt = 1.52% (Interest Expense 147.0k / Debt 9.67m)
Taxrate = 1.39% (43.0k / 3.10m)
NOPAT = 11.6m (EBIT 11.7m * (1 - 1.39%))
Current Ratio = 1.26 (Total Current Assets 29.3m / Total Current Liabilities 23.2m)
Debt / Equity = 0.17 (Debt 9.67m / totalStockholderEquity, last quarter 57.8m)
Debt / EBITDA = 0.18 (Net Debt 4.59m / EBITDA 25.9m)
Debt / FCF = 0.21 (Net Debt 4.59m / FCF TTM 21.5m)
Total Stockholder Equity = 54.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.90% (Net Income 11.2m / Total Assets 90.6m)
RoE = 20.58% (Net Income TTM 11.2m / Total Stockholder Equity 54.5m)
RoCE = 19.14% (EBIT 11.7m / Capital Employed (Equity 54.5m + L.T.Debt 6.73m))
RoIC = 20.49% (NOPAT 11.6m / Invested Capital 56.4m)
WACC = 10.77% (E(114.9m)/V(124.6m) * Re(11.55%) + D(9.67m)/V(124.6m) * Rd(1.52%) * (1-Tc(0.01)))
Discount Rate = 11.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 63.37%
[DCF Debug] Terminal Value 72.80% ; FCFF base≈18.1m ; Y1≈22.4m ; Y5≈38.1m
Fair Price DCF = 9.57 (EV 410.3m - Net Debt 4.59m = Equity 405.7m / Shares 42.4m; r=10.77% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 59.14 | EPS CAGR: 16.49% | SUE: -0.17 | # QB: 0
Revenue Correlation: -78.30 | Revenue CAGR: -4.87% | SUE: 1.72 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.02 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.14 | Chg30d=-0.008 | Revisions Net=+1 | Growth EPS=+42.1% | Growth Revenue=+11.0%